[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: Vitamin D Group with age normalized increase in Pulse wave velocity between 364-580 cm/sec (Arterial stiffness level: 20 Severe non ventilated patients in this group will receive vitamin D only with standard COVID-19 treatment as per institute COVID-19 therapy guidelinesIntervention2: Vitamin D Group with age normalized increase in Pulse wave velocity between 364-580 cm/sec ( Arterial stiffness level ): 20 Severe non ventilated patients in this Vitamin D Group will receive standard COVID-19 treatment; and in addition :Day 1;2 & 3: Vitamin D3 60;000 IU BLD along with Magnesium Glycinate 250mg BD. Day 4: Vitamin D3 60;000 IU BD along with Magnesium Glycinate 250mg BD. Day 5;6;7 : Vitamin D3 60;000 IU B along with Magnesium Glycinate 250mg B.Intervention3: CCB and ARB Active Therapy group with age normalized increase in Pulse wave velocity between 364-580 cm/sec (Arterial stiffness level): 20 Severe non ventilated patients in this CCB and ARB Active Therapy group will receive standard COVID-19 treatment and in addition :Day 1;2: Cilnidipine 10mg + Telmisartan 40 mg BDDay 3;4;5;6 &7: Cilnidipine 10mg + Telmisartan 40 mg BIntervention4: Vitamin D with CCB and ARB Active Therapy group \u00e2?? with age normalized increase in Pulse wave velocity between 364-580 cm/sec ( Arterial stiffness level ): 20 Severe non ventilated patients in this Vitamin D with CCB and ARB Active Therapy group will receive standard COVID-19 treatment and in addition :Day 1;2: Cilnidipine 10mg + Telmisartan 40 mg B. Vitamin D3 30;000 IU BLD alongwith Magnesium Glycinate 125mg BD.Day 3: Cilnidipine 5mg + Telmisartan 20 mg BVitamin D3 30;000 IU BLD alongwith Magnesium Glycinate 125mg BD.Day 4: Cilnidipine 5mg + Telmisartan 20 mg BVitamin D3 30;000 I", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "(1) Pulse wave velocity between 279-364 cm/sec (Arterial stiffness level) \nvs (2) Pulse wave velocity between 364-580 cm/sec (Arterial stiffness level) ", "treatment_id": 1466, "treatment_name": "Cilnidipine+telmisartan", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "(1) Pulse wave velocity between 279-364 cm/sec (Arterial stiffness level) \nvs (2) Pulse wave velocity between 364-580 cm/sec (Arterial stiffness level) ", "treatment_id": 2221, "treatment_name": "Magnesium sulfate+vitamin d3", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "(1) Pulse wave velocity between 279-364 cm/sec (Arterial stiffness level) \nvs (2) Pulse wave velocity between 364-580 cm/sec (Arterial stiffness level) ", "treatment_id": 2223, "treatment_name": "Cilnidipine+magnesium sulfate+telmisartan+vitamin d", "treatment_type": "Cardiovascular agents+vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "N/A", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: Vitamin D Group with age normalized increase in Pulse wave velocity between 364-580 cm/sec (Arterial stiffness level: 20 Severe non ventilated patients in this group will receive vitamin D only with standard COVID-19 treatment as per institute COVID-19 therapy guidelinesIntervention2: Vitamin D Group with age normalized increase in Pulse wave velocity between 364-580 cm/sec ( Arterial stiffness level ): 20 Severe non ventilated patients in this Vitamin D Group will receive standard COVID-19 treatment; and in addition :Day 1;2 & 3: Vitamin D3 60;000 IU BLD along with Magnesium Glycinate 250mg BD. Day 4: Vitamin D3 60;000 IU BD along with Magnesium Glycinate 250mg BD. Day 5;6;7 : Vitamin D3 60;000 IU B along with Magnesium Glycinate 250mg B.Intervention3: CCB and ARB Active Therapy group with age normalized increase in Pulse wave velocity between 364-580 cm/sec (Arterial stiffness level): 20 Severe non ventilated patients in this CCB and ARB Active Therapy group will receive standard COVID-19 treatment and in addition :Day 1;2: Cilnidipine 10mg + Telmisartan 40 mg BDDay 3;4;5;6 &7: Cilnidipine 10mg + Telmisartan 40 mg BIntervention4: Vitamin D with CCB and ARB Active Therapy group \u00e2?? with age normalized increase in Pulse wave velocity between 364-580 cm/sec ( Arterial stiffness level ): 20 Severe non ventilated patients in this Vitamin D with CCB and ARB Active Therapy group will receive standard COVID-19 treatment and in addition :Day 1;2: Cilnidipine 10mg + Telmisartan 40 mg B. Vitamin D3 30;000 IU BLD alongwith Magnesium Glycinate 125mg BD.Day 3: Cilnidipine 5mg + Telmisartan 20 mg BVitamin D3 30;000 IU BLD alongwith Magnesium Glycinate 125mg BD.Day 4: Cilnidipine 5mg + Telmisartan 20 mg BVitamin D3 30;000 I", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]